Literature DB >> 21901249

IKAROS isoform 6 enhances BCR-ABL1-mediated proliferation of human CD34+ hematopoietic cells on stromal cells.

Kei Suzuki1, Ryoichi Ono, Kohshi Ohishi, Masahiro Masuya, Itaru Kataoka, Bing Liu, Yoshiki Nakamori, Kazuko Ino, Fumihiko Monma, Hirofumi Hamada, Toshio Kitamura, Naoyuki Katayama, Tetsuya Nosaka.   

Abstract

The BCR-ABL1 induces chronic myelogenous leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL). Recent studies revealed high ratios of loss of the IKZF1 gene which encodes IKAROS in BCR-ABL1+ ALL and lymphoblastic crisis (LBC) of CML. However, little is known about the cooperativity between the aberrant IKAROS and BCR-ABL1 in primary human hematopoietic cells. We investigated the effects of expression of BCR-ABL1 and/or IK6, a natural dominant negative isoform of IKAROS, on proliferation and differentiation of human CD34+ cord blood cells with or without human bone marrow-derived stromal cells which support early B cell differentiation. Cell proliferation was remarkably enhanced by co-expression of BCR-ABL1 and IK6, with reduced expression of glycophorin A and increased expression of CD41, especially on stromal cells, compared with expression of BCR-ABL1 alone that resulted in expansion of erythroid progenitors. Interestingly, p190BCR-ABL1 showed higher dependency on stromal cells to stimulate cell growth with IK6, than p210BCR-ABL1. Furthermore, the cooperation was found to depend on direct cell adhesive interaction of hematopoietic progenitors with stromal cells. These findings suggest that IK6 and BCR-ABL1 synergistically contribute to leukemogenesis in human bone marrow stromal microenvironment, and may provide a clue to elucidate the mechanisms of leukemogenesis of Ph+ ALL and CML-LBC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21901249     DOI: 10.3892/ijo.2011.1192

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

Review 1.  The hematopoietic system in the context of regenerative medicine.

Authors:  Christopher D Porada; Anthony J Atala; Graça Almeida-Porada
Journal:  Methods       Date:  2015-08-28       Impact factor: 3.608

Review 2.  Genetic events other than BCR-ABL1.

Authors:  Paolo Neviani
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

3.  Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.

Authors:  J M Boer; A van der Veer; D Rizopoulos; M Fiocco; E Sonneveld; H A de Groot-Kruseman; R P Kuiper; P Hoogerbrugge; M Horstmann; M Zaliova; C Palmi; J Trka; E Fronkova; M Emerenciano; M do Socorro Pombo-de-Oliveira; W Mlynarski; T Szczepanski; K Nebral; A Attarbaschi; N Venn; R Sutton; C J Schwab; A Enshaei; A Vora; M Stanulla; M Schrappe; G Cazzaniga; V Conter; M Zimmermann; A V Moorman; R Pieters; M L den Boer
Journal:  Leukemia       Date:  2015-07-23       Impact factor: 11.528

4.  Human parainfluenza virus type 2 vector induces dendritic cell maturation without viral RNA replication/transcription.

Authors:  Kenichiro Hara; Masayuki Fukumura; Junpei Ohtsuka; Mitsuo Kawano; Tetsuya Nosaka
Journal:  Hum Gene Ther       Date:  2013-07       Impact factor: 5.695

Review 5.  Varied functions of immune checkpoints during cancer metastasis.

Authors:  Ali Safarzadeh; Mohsen Alizadeh; Fatemeh Beyranvand; Reza Falavand Jozaaee; Khalil Hajiasgharzadeh; Amir Baghbanzadeh; Afshin Derakhshani; Antonella Argentiero; Behzad Baradaran; Nicola Silvestris
Journal:  Cancer Immunol Immunother       Date:  2020-09-09       Impact factor: 6.968

6.  The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.

Authors:  Cinzia Fionda; Maria Pia Abruzzese; Alessandra Zingoni; Francesca Cecere; Elisabetta Vulpis; Giovanna Peruzzi; Alessandra Soriani; Rosa Molfetta; Rossella Paolini; Maria Rosaria Ricciardi; Maria Teresa Petrucci; Angela Santoni; Marco Cippitelli
Journal:  Oncotarget       Date:  2015-09-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.